Introduction
Since lung cancer is the most common cancer worldwide, it will probably remain the major cause of cancer deaths among both men and women at least in the initial period of the 21st century. The etiological factors are still unclear. However, it is clear that long-time cigarette smoking increases the risk of lung cancer. Benzo[a]pyrene (B[a]P) is one of the polycyclic aromatic hydrocarbons (PAH) found in tobacco smoke, and its metabolite benzo [a] pyrene diol epoxide (BPDE) is considered to be a classic DNA-damaging carcinogen (Denissenko, Pao et al., 1996; Li, Wang et al., 1996) . In several recent studies have demonstrated that the cytochrome P450 enzyme (CYPs) family plays an important role in the metabolism of pro-carcinogens, for example B[a]P and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to carcinogens (Hukkanen, Lassila et al., 2000; Vanden Heuvel, Clark et al., 1993; Hecht 1996; Rojas, Camus et al., 1992) . Several CYPs 1A1, 4B1, 2C, 2D6 and 2E1 are expressed in normal organs including the liver (Andersen, Farin et al., 1998) , lung (Li, Wang et al., 1996; Hukkanen, Hakkola et al., 1997) , bronchoalveolar macrophages (Hukkanen, Hakkola et al., 1997) and peripheral blood cells (Hukkanen, Hakkola et al., 1997; Krovat, Tracy et al., 2000) .
They are also expressed in malignant tissues, such as lung (Hukkanen, Lassila et al., 2000; Goto, Yoneda et al., 1996) , esophagus (Itoga, Nomura et al., 2002) , larynx (Agundez, Gallardo et al., 2001) , liver (Sumida, Fukuen et al., 2000) , and breast cancer (Xiong, Bondy et al., 2001) . Several previous studies demonstrated that B[a]P is metabolized in the lung microsomes and pulmonary alveolar microphages by CYPs 1A1, 4B1, and 2C (Hukkanen, Hakkola et al., 1997; Thompson, McCoy et al., 1989; McLemore, Martin et al., 1977) . The suitability of using CYPs expression in human lymphocytes as a biomarker of metabolism of pro-carcinogens was demonstrated in other reports (Li, Wang et al., 1996; Rojas, Camus et al., 1992) . Li, Wang et al., (1996) demonstrated both a high degree of interindividual variability in CYP1A1 inducibility, ANNALS OF Cancer Research and Therapy and a correlation between the level of its inducibility in lymphocytes and the risk of smoking-related lung cancer. Other in vitro studies have suggested that B[a]P is metabolized in lymphocytes (Okano, Miller et al., 1979; Gurtoo, Vaught et al., 1980) . Hukkanen, Hakkola et al., (1997) used reverse transcription polymerase chain reaction (RT-PCR) to evaluate the expression of CYPs in human bronchoalvealar and peripheral lymphocytes to assess the potential utility of peripheral lymphocytes as a surrogate for lung tissue. Law (1990) reported that peripheral lymphocytes can be used as a surrogate for lung tissue to study susceptibility to lung cancer. He found aryl hydrocarbon hydroxylase (AHH) activity was significantly higher in lung cancer cases in 13 (65%) out of 20 studies examining peripheral lymphocytes in case-control studies. Those reports indicate the CYP mRNA expression in peripheral lymphocytes can be used as an indicator of activating or inactivating pro-carcinogens. The metabolism of B(a)P is known very well (Li, Wang et al., 1996; Vanden Heuvel, Clark et al., 1993) . B(a)P is metabolized to DNA-binding diol epoxides by phase I CYPs and detoxified by phase II enzymes including glutathione S-transferase. The greater the activation of the phase I enzymes and the lower the detoxification of the phase II enzymes, the more they might be involved in the development of lung cancer (Goto, Yoneda et al., 1996; Rojas, Cascorbi et al., 2000; Quinones, Lucas et al., 2001; Hayashi, Watanabe et al., 1992) . Previous studies (Hayashi, Watanabe et al., 1992; Okada, Kawashima et al., 1994) demonstrated that the polymorphisms in CYP1A1, ml and m2 mutations are risk factors in Japanese smoking-related lung cancer. In addition, Quinones, Lucas et al., (2001) reported that the activated type polymorphism in CYP1A1 enzyme is frequently seen in lung cancer patients in Chile. Thus, we hypothesized that CYPs enzyme mRNA level of peripheral lymphocytes could be used as a biomarker for the risk of lung cancer. The present study is the first report on mRNA expression profiles for a number of targeted CYPs in peripheral lymphocytes from patients with lung cancer in comparison with healthy controls.
The semi-quantitative competitive reverse transcription polymerase chain reaction (QC-RT PCR) (Andersen, Farin et al., 1998; Krovat, Tracy et al., 2000; Sumida , with an average smoking index of 914.3 (range, 400-2500) were studied in the same period. All smokers in this study were current smokers and all non-smokers were defined as individuals who had never smoked. Age, gender and smoking states of lung cancer patients and healthy controls are listed in Table I . All patients were given an explanation of the nature of the study and their fully informed consent was obtained prior to obtaining blood samples.
Isolation of total RNA from peripheral blood Total RNA was extracted from 5ml of peripheral blood from pretreated patients by the QIAamp(R) reagent (QIAGEN, Hilden, Germany) following the manufacturer's protocol. To remove contaminating genomic DNA, extracted mRNA preparations were treated with RNase-free DNase I (QIAGEN). The isolated total RNA was stored at -85° C until use.
Primer design and generation of RNA competitor Gene-specific primers were designed to amplify the specific regions of CYPs 1A1, 1A2, 2A6/7, 2B6, 4B1, 2C, 2D6, 2E1 and glyceraldehyde-3-phosphate using reagents supplied in a commercial kit, Human Cytochrome P450 RT-PCR(R)® (TaKaRa Biomedicals, Tokyo, Japan). The primer sequence of each gene is considered proprietary information by the TaKaRa Company and is not made public. Table II . The transcription products of CYPs 1A1, 2B6, 4B1, 2C, 2D6 and 2E1 were detectable in both groups all objects. However, since CYPs 1A2 and 2A6/7 were not expressed in peripheral blood lymphocytes in either patients or healthy control groups, these enzymes were excluded from the analyses. The mRNA levels of CYPs 1A1 (p<0.001), 4B1 (p<0.001) and 2C (p<0.001) in the lung cancer group were higher than those in the healthy control group. However, CYPs 2D6 (p<0.0001) and 2E1 (p<0.0001) mRNA levels in the lung cancer group were lower than those in the healthy control group.
In smokers, the mRNA levels of CYPs 1A1 (p<0.01), 4B1 (p<0.001), and 2C (p<0.001) were also higher, and CYPs 2D6 (p<0.0001) and 2E1 (p<0.001) were also lower in the lung cancer group than healthy controls (Table III) . There were no differences in CYPs mRNA expression between adenocarcinomas and squamous cell carcinomas (data not shown) or between all studied smokers and non-smokers (Table   IV ANNALS OF Cancer Research and Therapy mitogen-stimulated lymphocytes and lung tissue, especially the relationship between CYP1A1 induction by exposure to PAH in cigarette smoke and susceptibility to lung cancer (Denissenko, Pao et al., 1996; Hecht 1996; Goto, Yoneda et al., 1996) . Recent genetic polymorphism studies demonstrated that CYP1A1 affects BPDE-DNA binding in human leukocytes, and exposure to PAH have a synergistic effect. High levels of BPDE-DNA adducts in leukocytes by specific phase I, phase II enzyme genotype combinations may relate to the increased risk for lung cancer (Rojas, Cascorbi et al., 2000) .
Specific polymorphism within the CYP1A1 gene was found to be associated with increased risk of lung cancer in Japanese smokers (Goto, Yoneda et al., 1996; Hayashi, Watanabe et al., 1992; Okada, Kawashima et al., 1994) , and similar results were obtained by other ethnic polymorphism studies (Rojas, Cascorbi et al., 2000; Quinones, Lucas et al., 2001; Alexandrov, Cascorbi et al., 2002) . Expression of CYP1A1 levels were significantly related to the hydrophobic DNA adduct levels, although a large interindividual variation was observed for both CYP1A1 expression and DNA adducts (Mollerup, Ryberg et al., 1999) . Several studies demonstrated a significant correlation between CYP1A1 expression and DNA adducts level (Vanden Heuvel, Clark et al., 1993; Krovat, Tracy et al., 2000; Mollerup, Ryberg et al., 1999) . Imaoka, Yoneda et al., (2000) and Fujitaka, Oguri et al., (2001) In the present study, CYPs 2D6 and 2E1 were more highly expressed in healthy controls than in patients with lung cancer. Krovat, Tracy et al., (2000) reported that these ANNALS OF Cancer Research and Therapy enzymes were typically expressed at the highest levels in peripheral lymphocytes from healthy donors. Genetic polymorphism of the human CYPs 2D6 and 2E1 genes are known to be associated with lung cancer risk in some reports (Agundez, Gallardo et al., 2001; Quinones, Lucas et al, 2001 ). Conversely, in other reports these polymorphisms are related to low risk for lung cancer (Ayesh, Idle et al., 1984) . Kiyohara, Otsu et al., (2002) This suggests that these enzymes are not induced in peripheral blood lymphocytes by smoking. We believe, therefore, CYPs expression in peripheral lymphocytes can be used as biomarkers for the risk of lung cancer. This finding was previously confirmed by other reports. Thompson, McCoy et al., (1989) found that s moking does not influence metabolism or DNA adduct formation in lymphocytes. Rojas, Camus et al., (1992) found that metabolic activities for B[a]P-7,8-diol to tetrol conversion are similar in smokers and non-smokers.
In conclusion, increased expression of CYPs 1A1, 4B1 and 2C enzymes in peripheral blood lymphocytes was found in lung cancer patients in comparison with healthy controls. Therefore, increased expression of these enzymes may possibly be susceptibility biomarkers for human lung cancer.
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